Celgene (CELG) Stock Research, Analysis & News

Quick Analysis on Celgene (CELG) Stock as of June 25, 2018

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Celgene (CELG) Stock below)

Celgene (CELG) Stock Profile Summary

Celgene Corporation discovers, develops, and commercializes innovative therapies to treat cancer and immune-inflammatory diseases in the United States, Europe, and internationally. Its commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as patients with transfusion-dependent anemia; and THALOMID to treat, in combination with dexamethasone, patients with newly diagnosed multiple myeloma, as well as for the prevention and suppression of cutaneous manifestations of erythema nodosum leprosum recurrence. The company also sells VIDAZA, used to subtypes of myelodysplastic syndromes; RITALIN to treat attention deficit hyperactivity disorder; FOCALIN to prevent oncology-related disorders; and ALKERAN to treat multiple myeloma and carcinoma of the ovary. Its development stage products consist of CC-4047, which is in Phase I and Phase II clinical trials for treating disease indications, including sickle cell anemia, myelofibrosis, and multiple myeloma; CC-10004, a Phase II clinical trial product for psoriasis and psoriatic arthritis; CC-11050, a Phase I clinical trial completed product for inflammatory conditions; CC-401, a Phase I clinical trial completed product to identify kinases that regulate pathways critical in inflammation and oncology; CC-930, a Phase Ib clinicial trial completed product for fibrotic conditions; and Amrubicin, a Phase III clinical trial product for small cell lung cancer treatment. In addition, the company is researching stem cells derived from the human placenta, as well as from the umbilical cord. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. and Agios Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Celgene (CELG) Stock Key Statistics Research and Analysis as of June 25, 2018

Celgene (CELG) Stock Competitor Research and Analysis

Amgen Inc. (AMGN)AstraZeneca PLC (AZN)
Bristol-Myers Squibb Company (BMY)Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)

Mutual Funds with Celgene (CELG) Stock in its top 10 holdings

FundCategoryCELG Holding Percentage
Invesco Summit ALarge Growth2.14%
Brown Capital Mgmt Mid-Cap InvMid-Cap Growth3.11%
Biondo Focus InvestorLarge Growth8.29%
Biondo Growth InvLarge Growth6.65%
ProFunds Biotechnology UltraSector InvTrading--Leveraged Equity8.07%
Bridges InvestmentLarge Growth4.22%
Invesco Summit BLarge Growth2.14%
PL Growth LT 529 MT ALarge Growth3.35%
Invesco Summit CLarge Growth2.14%
Delaware US Growth CLarge Growth5.01%
Delaware US Growth InstlLarge Growth5.01%

ETFs with Celgene (CELG) Stock in its top 10 holdings

Stock Research on Celgene (CELG)

Latest Market News on Celgene (CELG)


Click here to find the latest news on Celgene (CELG)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Amgen Inc. (AMGN)
AstraZeneca PLC (AZN)
Bristol-Myers Squibb Company (BMY)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Pfizer Inc. (PFE)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)